Andrew Scott

Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Kate Manos, Geoffrey Chong, Colm Keane, Sze-Ting Lee, Charmaine Smith, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, Melinda Burgess, Niles Elizabeth Nelson, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, Chun Yew Fong, Eliza A Hawkes

Journal article  |  2023  |  LEUKEMIA

Immune evasion, due to abnormal expression of programmed-death ligands 1 and 2 (PD-L1/PD-L2), predicts poor outcomes with chemoimm..

Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).

Brian M Shuch, Allan J Pantuck, Jean-Christophe Bernhard, Michael A Morris, Viraj A Master, Andrew Mark Scott, Charles Van Praet, Clément Bailly, Tamer Aksoy, Robin Merkx, David M Schuster, Sze Ting Lee, Neeta Pandit-Taskar, Alice C Fan, Libuse Tauchmanova, Phillip Allman, Kavita Vadali, Colin Hayward, Peter Mulders

Journal article  |  2023  |  Journal of Clinical Oncology

LBA602 Background: The increasing detection of renal masses presents a significant patient management challenge. Diagnostic optio..

Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: A post hoc analysis of the PROPS trial.

Samuel Tremblay, Mofarej Alhogbani, Andrew Weickhardt, Ian D Davis, Andrew Mark Scott, Rodney J Hicks, Ur Metser, Sue Chua, Reena Davda, Shonit Punwani, Heather Ann Payne, Nina Tunariu, Bao Ho, Sympascho Young, Glenn Bauman, Louise Emmett, Frederic Pouliot

Journal article  |  2023  |  Journal of Clinical Oncology

316 Background: The impact of molecular imaging (MI) on patient management after biochemical recurrence (BCR) following radical p..

Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography

Catherine G Fitzgerald Dickmann, Alexander FF McDonald, Nhi Huynh, Angela Rigopoulos, Zhanqi Liu, Nancy Guo, Laura DD Osellame, Michael AA Gorman, Michael WW Parker, Hui KK Gan, Andrew MM Scott, Uwe Ackermann, Ingrid JG Burvenich, Jonathan MM White

Journal article  |  2023  |  CHEMICAL COMMUNICATIONS

Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. ..

18F-labeling and initial in vivo evaluation of a Hitomi peptide for imaging tissue transglutaminase 2.

Uwe Ackermann, Luise Jäger, Angela Rigopoulos, Ingrid Julienne Georgette Burvenich, Graeme Joseph O'Keefe, Andrew M Scott

Journal article  |  2023  |  Nucl Med Biol

INTRODUCTION: Tissue transglutaminase 2 (TG2) is a calcium-dependent enzyme which cross-links proteins. It is overexpressed in man..

Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors.

E Lopci, N Aide, A Dimitrakopoulou-Strauss, L Dercle, A Iravani, RD Seban, C Sachpekidis, O Humbert, O Gheysens, AWJM Glaudemans, WA Weber, AD Van den Abbeele, RL Wahl, AM Scott, N Pandit-Taskar, RJ Hicks

Journal article  |  2022  |  Cancer Imaging

Response assessment in the context of immunomodulatory treatments represents a major challenge for the medical imaging community a..

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.

Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, Tim Akhurst, Peter Roselt, Jenny Trinh, Thomas John, Lisa Devereux, Paul S Donnelly, Rod Hicks, Andrew M Scott, Daniel Steinfort, Stephen Fox, Benjamin Blyth, Sagun Parakh, Gerard G Hanna, Jason Callahan, Kate Burbury, Michael MacManus

Journal article  |  2022  |  BMJ Open

BACKGROUND: ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if 89Zr-durvalumab PET/CT can be used t..

Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy.

Zhipeng Cao, Ingrid J Burvenich, Kening Zhao, Clare Senko, Jason Glab, Renee Fogliaro, Zhanqi Liu, Irvin Jose, Hamsa Puthalakath, Nick J Hoogenraad, Laura D Osellame, Andrew M Scott

Journal article  |  2022  |  Cancers (Basel)

BACKGROUND: Developing therapies for cancer cachexia has not been successful to date, in part due to the challenges of achieving r..

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [Lu-177]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial

James P Buteau, Andrew J Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M Joshua, Roslyn J Francis, Alison Y Zhang, Andrew M Scott, Sze-Ting Lee, Arun A Azad, Margaret M McJannett, Martin R Stockler, Scott G Williams, Ian Davis, Michael S Hofman

Journal article  |  2022  |  LANCET ONCOLOGY

BACKGROUND: Previously, results from the TheraP trial showed that treatment with lutetium-177 [177Lu]Lu-PSMA-617 improved frequenc..

Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition.

Roger J Daly, Andrew M Scott, Oliver Klein, Matthias Ernst

Journal article  |  2022  |  Mol Cancer

Over the past decade, immune checkpoint inhibitor (ICI) therapy has been established as the standard of care for many types of can..